Search results for "Nausea"

showing 10 items of 138 documents

Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma

2000

The efficacy of oxaliplatin combined with high-dose 5-fluorouracil (5-FU) and folinic acid (FA) as an outpatient salvage treatment for patients with metastasized colorectal cancer was retrospectively analyzed in one center. Tumor progression had occurred for the majority of patients during two regimens (n = 11) otherwise during one (n = 1) regimen of prior 5-FU-based chemotherapy, which had been applied in a standardized sequential fashion. As third-line therapy oxaliplatin was infused intravenously over 2 h at a dose of 60 mg/m2 prior to a 2-h infusion of FA (500 mg/m2). 5-FU (2,600 mg/m2) was subsequently given over 24 h. A favorable response was observed in 9/12 (75%) of the heavily pret…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsNauseaColorectal cancermedicine.medical_treatmentLeucovorinGastroenterologyDisease-Free SurvivalDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineInfusions IntravenousAgedNeoplasm StagingRetrospective StudiesSalvage TherapyChemotherapyDose-Response Relationship Drugbusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseOxaliplatinOxaliplatinRegimenFluorouracilColon neoplasmFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Development and validation of the Migraine Screen Questionnaire (MS-Q).

2005

Aim.—To develop and evaluate the clinimetric properties of a new migraine screening questionnaire: the Migraine Screen Questionnaire (MS-Q). Background.—Migraine is a public health problem requiring screening programs and tools to ensure early detection. Methods.—A questionnaire was developed based on the criteria of the International Headache Society (IHS) and a review of the literature by a committee of experts. Stage I: The original version of the MS-Q was distributed by mail and completed by Pfizer employees and self-administered to neurological patients; all subjects were afterward evaluated by a neurologist who was blinded to the MS-Q results, to establish an independent IHS diagnosis…

AdultMalemedicine.medical_specialtybusiness.industryNauseaMigraine DisordersValidityReproducibility of ResultsNeurological disordermedicine.diseaseLogistic regressionConfidence intervalClinical trialLogistic ModelsNeurologyMigraineCronbach's alphaSurveys and QuestionnairesPhysical therapyMedicineHumansFemaleNeurology (clinical)medicine.symptombusinessHeadache
researchProduct

Metoclopramide and diphenhydramine in the treatment of hyperemesis gravidarum: effectiveness and predictors of rehospitalisation.

2007

Abstract Objectives Hyperemesis gravidarum (HG) is the second most common reason for hospitalisation during pregnancy. Since 2002, a new HG treatment protocol consisting of metoclopramide plus diphenhydramine was put in place at CHU Sainte-Justine, affiliated to University of Montreal, Quebec, Canada. The objectives of this study were to evaluate the effectiveness of this new HG protocol regarding length of hospitalisation for HG, rate of rehospitalisation, evolution of nausea and vomiting symptoms, and rate of adverse events. Study design A retrospective cohort study was conducted from 2002 to 2006 on the population of pregnant women diagnosed with HG, and treated at CHU Sainte-Justine wit…

AdultMetoclopramideAdolescentNauseamedicine.drug_classMetoclopramidePopulationPatient ReadmissionCohort StudiesHyperemesis gravidarumYoung AdultSex FactorsPregnancyHyperemesis GravidarumMorning sicknessmedicineAntiemeticHumanseducationRetrospective Studieseducation.field_of_studybusiness.industryDiphenhydraminePregnancy OutcomeObstetrics and GynecologyLength of Staymedicine.diseaseDiphenhydramineTreatment OutcomeReproductive MedicineAnesthesiaAntiemeticsDrug Therapy CombinationFemalemedicine.symptombusinessDroperidolmedicine.drugEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Oral versus intravenous vinorelbine: clinical safety profile

2005

The availability of chemotherapeutic drugs administrable by oral route represents a step forward in the management of cancer patients. Among oral agents, vinorelbine is particularly interesting for its pharmacological characteristics and clinical efficacy. Oral vinorelbine is rapidly absorbed (1.5-3 hours) with an elimination half-life of approximately 40 hours. It shows a low level of binding to plasma proteins (13%), is highly bound to platelets (78%) and has a hepatic metabolism and an absolute bioavailability of 40% with a moderate and similar interpatient variability for the two forms. Food has no influence on the pharmacokinetic profile of oral vinorelbine even if nausea/vomiting is l…

AdultNauseaAdministration OralBiological AvailabilityPharmacologyVinblastineVinorelbineAbsorptionEatingTherapeutic indexCytochrome P-450 Enzyme SystemPharmacokineticsOral administrationNeoplasmsmedicineHumansPharmacology (medical)Infusions IntravenousAgedbreast cancer non-small cell lung cancer (NSCLC) oral vinorelbinebusiness.industryStandard treatmentAge FactorsVinorelbineGeneral MedicineMiddle AgedAntineoplastic Agents PhytogenicLiverVomitingmedicine.symptombusinessDrug metabolismHalf-Lifemedicine.drug
researchProduct

Gynecological adverse effects of natalizumab administration: Case report and review of the literature.

2018

Abstract Background Natalizumab is administered for the treatment of relapsing-remitting multiple sclerosis (RR-MS) with high disease activity.Natalizumab therapy has been associated with adverse effects, such as progressive multifocal leukoencephalopathy, liver damage, nasopharyngitis, urinary tract infection, urticaria, cephalgia, dizziness, fatigue, nausea, fever, rigidity, anxiety and gastroenteritis. Objective To describe a case of a woman with RR-MS who developed recurrent vaginitis on natalizumab administration. Methods Case report and review of the literature. Results The case of a 26-year-old Caucasian woman with RR-MS, who presented with recurrent vaginitis since the initiation of…

AdultPediatricsmedicine.medical_specialtyNauseaUrinary systemDisease03 medical and health sciences0302 clinical medicineNatalizumabMultiple Sclerosis Relapsing-RemittingmedicineHumansImmunologic Factors030212 general & internal medicineAdverse effectVaginitisbusiness.industryProgressive multifocal leukoencephalopathyMultiple sclerosisNatalizumabGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingNeurologyFemaleNeurology (clinical)medicine.symptombusinessGenital Diseases Female030217 neurology & neurosurgerymedicine.drugFollow-Up StudiesMultiple sclerosis and related disorders
researchProduct

Analysis of Safety and Tolerability Data Obtained from Over 1,500 Patients Receiving Topiramate for Migraine Prevention in Controlled Trials

2008

Objective.  Topiramate is an effective and generally well-tolerated migraine preventive therapy, as shown in three large, randomized, double-blind, placebo-controlled registration trials. Based upon efficacy/tolerability, topiramate 100 mg/day (50 mg BID) is the recommended target dose for most patients with migraine. To further assess the safety and tolerability of topiramate for migraine prevention, we analyzed safety data from 1,580 patients who participated in the three pivotal registration trials or an earlier pilot, randomized, double-blind, placebo-controlled trial. Methods.  The safety population consisted of all patients who took ≥1 dose of study medication during the double-blind …

AdultTopiramateAdolescentNauseaMigraine DisordersPopulationPhysical examinationFructosePlaceboTopiramatemedicineHumansChildAdverse effecteducationAgedRandomized Controlled Trials as Topiceducation.field_of_studymedicine.diagnostic_testbusiness.industryPatient SelectionDrug ToleranceGeneral MedicineMiddle Agedmedicine.diseaseNeuroprotective AgentsAnesthesiology and Pain MedicineTolerabilityMigraineAnesthesiaNeurology (clinical)Safetymedicine.symptombusinessmedicine.drugPain Medicine
researchProduct

Hormonal and psychological factors linked to the increased thermic effect of food in malnourished fasting anorexia nervosa

2007

In patients with anorexia nervosa (AN), weight gain is lower than that expected from the energy content of the meals. Thus we investigated the thermic effect of food (TEF) in relation to subjective feelings and plasma hormone levels in a group of AN patients.TEF, feelings (14 items), and plasma release of beta-endorphin, ACTH, cortisol, dopamine, and catecholamines were evaluated in 15 AN patients (body mass index, 13.6 +/- 1.2 kg.m(-2)) and in 15 healthy women after three gastric loads (0, 300, 700 kcal) infused by a nasogastric tube in a blind design.In AN, the blind loads induced an energy-dependent increase in TEF (P0.001), which was higher than that observed in healthy women (P0.001). …

Adultmedicine.medical_specialtyAnorexia NervosaCalorieAdolescentEndocrinology Diabetes and MetabolismClinical BiochemistrySensationBiochemistryBody Mass IndexNorepinephrine (medication)EatingEndocrinologyDouble-Blind MethodInternal medicinemedicineHumansComputingMilieux_MISCELLANEOUSHydrocortisone[SCCO.NEUR]Cognitive science/NeuroscienceMalnutritionBiochemistry (medical)[SCCO.NEUR] Cognitive science/NeuroscienceNauseaFastingHormonesAffectEndocrinologyAnorexia nervosa (differential diagnoses)[ SCCO.NEUR ] Cognitive science/NeuroscienceBody CompositionFemalemedicine.symptomSpecific dynamic actionEnergy IntakeEnergy MetabolismBody mass indexWeight gainBody Temperature Regulationmedicine.drugHormone
researchProduct

Cost analysis of target-controlled infusion-based anesthesia compared with standard anesthesia regimens.

2000

UNLABELLED With the development of new computer-assisted target-controlled infusion (TCI) systems and the availability of short-acting anesthetics, total IV anesthesia (TIVA) has become increasingly popular. The aim of this study was to compare costs of TCI-based anesthesia with two standard anesthesia regimens. Sixty patients undergoing elective laparoscopic cholecystectomy were randomly divided into three groups. Group 1 (TIVA/TCI) received TIVA using a propofol-based TCI system and continuous administration of remifentanil; Group 2 (isoflurane) underwent inhaled anesthesia with isoflurane, fentanyl, and N2O; Group 3 (standard propofol) received fentanyl and N2O and a continuous infusion …

Adultmedicine.medical_specialtyCost-Benefit AnalysisRemifentanilAnesthesia GeneralFentanylPacuRemifentanilDrug Delivery SystemsPiperidinesMedicineHumansInfusions IntravenousPropofolInfusion PumpsAgedbiologyIsofluranebusiness.industryMiddle Agedbiology.organism_classificationSurgeryFentanylRegimenAnesthesiology and Pain MedicineIsofluraneAnesthesiaAnestheticAnesthetics Inhalationmedicine.symptombusinessPropofolPostoperative nausea and vomitingAnesthetics Intravenousmedicine.drugAnesthesia and analgesia
researchProduct

The influence of oral contraceptives on the composition of bile.

1982

The increased risk of cholelithiasis during intake of oral contraceptives may be due to estrogen-induced saturation of the bile with cholesterol. In a randomized, prospective, crossed-over double-blind study 20 healthy women after roentgenological exclusion of gall-stones received either 1.0 mg of norethindrone acetate and 50 microgram ethinyl estradiol daily - as usual in oral contraception - for 21 days with 7 days of placebo treatment in each cycle or one fifth of this hormone dose in form of a continuous daily medication. After a 4 month's treatment the medication form was crossed-over. At the beginning of the study, before the cross-over and after the study bile was collected by duoden…

Adultmedicine.medical_specialtyNauseamedia_common.quotation_subjectGallbladder diseasePhysiologyEthinyl EstradiolContraceptives Oral HormonalMenstruationchemistry.chemical_compoundCholelithiasisInternal medicineDrug DiscoverymedicineBileHumansProspective cohort studyGenetics (clinical)Menstrual cyclemedia_commonbusiness.industryCholesterolGeneral Medicinemedicine.diseaseEndocrinologyCholesterolchemistryHormonal contraceptionVomitingMolecular MedicineFemalemedicine.symptomNorethindronebusinessContraceptives OralKlinische Wochenschrift
researchProduct

Cizolirtine Citrate, an Effective Treatment for Symptomatic Patients with Urinary Incontinence Secondary to Overactive Bladder: A Pilot Dose-Finding …

2009

Abstract Background A dose-finding study was performed as the first step in the clinical development of the new drug, cizolirtine citrate. Objective To assess the efficacy and safety of cizolirtine citrate in overactive bladder with urinary incontinence. Design, setting, and participants Seventy-nine outpatients with clinical overactive bladder and/or urodynamic diagnosis of detrusor overactivity were randomized in a multicentre, 12-wk, double-blind, pilot trial. Interventions Patients received cizolirtine citrate 400mg bid (C400), cizolirtine citrate 200mg bid (C200), or placebo. Measurements Patients recorded efficacy variables in 7- and 14-d bladder diaries: urinary incontinence episodes…

Adultmedicine.medical_specialtyVomitingCalcitonin Gene-Related PeptideUrologyUrinary systemVision DisordersUrologyPilot ProjectsUrinary incontinenceSubstance PPlaceboDizzinesslaw.inventionYoung AdultDouble-Blind MethodRandomized controlled triallawmedicineHumansAdverse effectAgedAged 80 and overUrinary bladderDose-Response Relationship DrugUrinary Bladder Overactivebusiness.industryNauseaMiddle Agedmedicine.diseaseUrodynamicsUrinary Incontinencemedicine.anatomical_structureTolerabilityOveractive bladderPyrazolesFemalemedicine.symptombusinessEuropean Urology
researchProduct